Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer
Stephen P. Hack, Wendy Verret, Sohail Mulla, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 85
Gallbladder cancer: current and future treatment options
Yanzhao Zhou, Kun Yuan, Yi Yang, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 40
Prognostic and Predictive Molecular Markers in Cholangiocarcinoma
Sandra Pavicevic, Sophie Reichelt, Deniz Uluk, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 1026-1026
Open Access | Times Cited: 30
Revisiting targeted therapy and immunotherapy for advanced cholangiocarcinoma
Jiajia Du, Xing Lv, Zunyi Zhang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 21
Current Standards, Multidisciplinary Approaches, and Future Directions in the Management of Extrahepatic Cholangiocarcinoma
Margaret Wheless, Rajiv Agarwal, Laura W. Goff, et al.
Current Treatment Options in Oncology (2024) Vol. 25, Iss. 1, pp. 127-160
Open Access | Times Cited: 7
Unresectable biliary tract cancer: Current and future systemic therapy
Danmei Zhang, Klara Dorman, C. Benedikt Westphalen, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114046-114046
Open Access | Times Cited: 7
Evolving Role of Immunotherapy in Advanced Biliary Tract Cancers
Sandra Kang, Bassel F. El‐Rayes, Mehmet Akce
Cancers (2022) Vol. 14, Iss. 7, pp. 1748-1748
Open Access | Times Cited: 24
Immune microenvironment of cholangiocarcinoma: Biological concepts and treatment strategies
Xianzhe Yu, Lingling Zhu, Ting Wang, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Efficacy and conversion outcome of chemotherapy combined with PD-1 inhibitor for patients with unresectable or recurrent gallbladder carcinoma: a real-world exploratory study
Qinqin Liu, Jian Yan, Yan‐Fang Ye, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Analysis of the effectiveness and safety of lenvatinib/bevacizumab combined with PD-1/PD-L1 inhibitors and GEMOX in the first-line treatment of advanced biliary tract carcinoma
Lu Zhao, Zhengfeng Zhang, Dazhen Wang, et al.
Clinical and Experimental Medicine (2025) Vol. 25, Iss. 1
Open Access
Quality of Life and Symptom Management in Advanced Biliary Tract Cancers
Lindsay Hunter, Heloisa P. Soares
Cancers (2021) Vol. 13, Iss. 20, pp. 5074-5074
Open Access | Times Cited: 23
VISTA Expression on Cancer-Associated Endothelium Selectively Prevents T-cell Extravasation
Sietse J. Luk, Rouven Schoppmeyer, Marieke E. Ijsselsteijn, et al.
Cancer Immunology Research (2023) Vol. 11, Iss. 11, pp. 1480-1492
Open Access | Times Cited: 8
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework
Colby S. Shemesh, Phyllis Chan, Mathilde Marchand, et al.
Clinical Pharmacology & Therapeutics (2023) Vol. 114, Iss. 3, pp. 644-651
Closed Access | Times Cited: 7
Complete remission in a pretreated, microsatellite-stable, KRAS-mutated colon cancer patient after treatment with sintilimab and bevacizumab and platinum-based chemotherapy: a case report and literature review
Lijuan He, Haiyuan Li, Yunpeng Wang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions
GuanBo Zhang, Jinsong Li, Gang Li, et al.
Clinical and Experimental Medicine (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial
Teresa Macarulla, Zhenggang Ren, Hong Jae Chon, et al.
Journal of Clinical Oncology (2024)
Closed Access | Times Cited: 2
Targeting Angiogenesis in the Era of Biliary Tract Cancer Immunotherapy: Biological Rationale, Clinical Implications, and Future Research Avenues
Annalisa Schirizzi, G Leonardis, V. Lorusso, et al.
Cancers (2023) Vol. 15, Iss. 8, pp. 2376-2376
Open Access | Times Cited: 6
Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
Taotao Zhou, Robert Mahn, Christian Möhring, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 9
Perioperative and palliative systemic treatments for biliary tract cancer
Hossein Taghizadeh, Yawen Dong, Thomas Gruenberger, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 1
Advancing immunotherapy for intrahepatic cholangiocarcinoma: exploring the tumor immune microenvironment and innovative treatments
Pengcheng Wei, Li Zhao
Hepatoma Research (2024)
Open Access | Times Cited: 1
Molecular Targets and Emerging Therapies for Advanced Gallbladder Cancer
Matteo Canale, Manlio Monti, Ilario Giovanni Rapposelli, et al.
Cancers (2021) Vol. 13, Iss. 22, pp. 5671-5671
Open Access | Times Cited: 11
Signaling and molecular networks related to development and inflammation involved in CCA initiation and progression
Antonio Cigliano, Alastair J. Strain, Massimiliano Cadamuro
Hepatoma Research (2023) Vol. 9, Iss. 14, pp. 14-14
Open Access | Times Cited: 3
Prediction of angiogenesis in extrahepatic cholangiocarcinoma using MRI-based machine learning
Jiong Liu, Mali Liu, Yaolin Gong, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 3
Treatment of biliary tract carcinoma over the last 30 years
Yutaka Midorikawa
BioScience Trends (2022) Vol. 16, Iss. 3, pp. 189-197
Open Access | Times Cited: 4
Long survival after immunotherapy plus paclitaxel in advanced intrahepatic cholangiocarcinoma: A case report and review of literature
Mengye He, Feifei Yan, Kai-Li Cen, et al.
World Journal of Clinical Cases (2022) Vol. 10, Iss. 32, pp. 11889-11897
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top